Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
P10s-PADRE Vaccine + Neoadjuvant Chemotherapy in ER+, HER2- Breast Cancer
NCT02229084Phase 2Completed
- Sponsor
- University of Arkansas
- Start
- Jan 2015
- Primary completion
- Jan 2023
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of P10s-PADRE in breast cancer, sponsored by University of Arkansas. Started Jan 2015; status: completed.
02
Drugs
P10s-PADRE
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02229084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02229084.